Immuneering Corp Stock Analysis
| IMRX Stock | USD 1.80 0.15 9.09% |
Immuneering Corp is undervalued with Real Value of 4.47 and Target Price of 12.42. The main objective of Immuneering Corp stock analysis is to determine its intrinsic value, which is an estimate of what Immuneering Corp is worth, separate from its market price. There are two main types of Immuneering Corp's stock analysis: fundamental analysis and technical analysis.
The Immuneering Corp stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Immuneering Corp is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Immuneering Stock trading window is adjusted to America/New York timezone.
Immuneering |
Immuneering Stock Analysis Notes
About 28.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.34. Some equities with similar Price to Book (P/B) outperform the market in the long run. Immuneering Corp recorded a loss per share of 2.04. The entity had not issued any dividends in recent years. Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited. Immuneering Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 74 people. To learn more about Immuneering Corp call the company at 617 500 8080 or check out https://immuneering.com.Immuneering Corp Investment Alerts
| Immuneering Corp generated a negative expected return over the last 90 days | |
| Immuneering Corp may become a speculative penny stock | |
| Immuneering Corp has high historical volatility and very poor performance | |
| Immuneering Corp has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (61.04 M) with profit before overhead, payroll, taxes, and interest of 158.83 K. | |
| Immuneering Corp currently holds about 128.1 M in cash with (55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.85, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Immuneering Corp has a frail financial position based on the latest SEC disclosures | |
| Roughly 28.0% of the company shares are held by company insiders | |
| Latest headline from gurufocus.com: Immuneering Corporation Announces Grant of Inducement Award |
Immuneering Corp Upcoming and Recent Events
Earnings reports are used by Immuneering Corp to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Immuneering Largest EPS Surprises
Earnings surprises can significantly impact Immuneering Corp's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-03-01 | 2023-12-31 | -0.47 | -0.52 | -0.05 | 10 | ||
2024-08-07 | 2024-06-30 | -0.5267 | -0.47 | 0.0567 | 10 | ||
2023-11-09 | 2023-09-30 | -0.49 | -0.43 | 0.06 | 12 |
Immuneering Stock Institutional Investors
| Shares | Hightower Advisors, Llc | 2024-12-31 | 71.4 K | Ci Private Wealth Llc | 2024-12-31 | 63.7 K | Exchange Traded Concepts, Llc | 2024-12-31 | 58.3 K | Ubs Group Ag | 2024-12-31 | 52.5 K | Bridgeway Capital Management, Llc | 2024-12-31 | 51.3 K | Two Sigma Investments Llc | 2024-12-31 | 50.6 K | Tidemark Llc | 2024-12-31 | 44.4 K | Northern Trust Corp | 2024-12-31 | 39.7 K | Xtx Topco Ltd | 2024-12-31 | 32.6 K | Vanguard Group Inc | 2024-12-31 | 1.1 M | T. Rowe Price Associates, Inc. | 2024-12-31 | 767.1 K |
Immuneering Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 55.89 M.Immuneering Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.34) | (1.27) | |
| Return On Capital Employed | (1.42) | (1.35) | |
| Return On Assets | (1.16) | (1.22) | |
| Return On Equity | (1.47) | (1.40) |
Management Efficiency
Immuneering Corp has return on total asset (ROA) of (0.4235) % which means that it has lost $0.4235 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7181) %, meaning that it created substantial loss on money invested by shareholders. Immuneering Corp's management efficiency ratios could be used to measure how well Immuneering Corp manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -1.27 in 2025. Return On Capital Employed is likely to rise to -1.35 in 2025. At this time, Immuneering Corp's Total Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 1.4 M in 2025, whereas Net Tangible Assets are likely to drop slightly above 65.1 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.4 K | 1.4 K | |
| Tangible Book Value Per Share | 1.1 K | 1.2 K | |
| Enterprise Value Over EBITDA | 0.50 | 0.52 | |
| Enterprise Value Multiple | 0.50 | 0.52 | |
| Enterprise Value | 177 M | 315.5 M |
The strategic initiatives led by Immuneering Corp's management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Technical Drivers
As of the 23rd of March, Immuneering Corp retains the Risk Adjusted Performance of 0.0555, downside deviation of 4.91, and Market Risk Adjusted Performance of 0.2808. Immuneering Corp technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Immuneering Corp Price Movement Analysis
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Immuneering Corp middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Immuneering Corp. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Immuneering Corp Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Immuneering Corp insiders, such as employees or executives, is commonly permitted as long as it does not rely on Immuneering Corp's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Immuneering Corp insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Immuneering Corp Outstanding Bonds
Immuneering Corp issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Immuneering Corp uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Immuneering bonds can be classified according to their maturity, which is the date when Immuneering Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US45258LAA52 Corp BondUS45258LAA52 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Immuneering Corp Predictive Daily Indicators
Immuneering Corp intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Immuneering Corp stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Immuneering Corp Forecast Models
Immuneering Corp's time-series forecasting models are one of many Immuneering Corp's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Immuneering Corp's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Immuneering Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Immuneering Corp prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Immuneering shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Immuneering Corp. By using and applying Immuneering Stock analysis, traders can create a robust methodology for identifying Immuneering entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (183.28) | (174.11) | |
| Operating Profit Margin | (187.75) | (178.36) | |
| Net Loss | (178.81) | (169.87) | |
| Gross Profit Margin | 0.45 | 0.35 |
Current Immuneering Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Immuneering analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Immuneering analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 12.42 | Buy | 7 | Odds |
Most Immuneering analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Immuneering stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Immuneering Corp, talking to its executives and customers, or listening to Immuneering conference calls.
Immuneering Stock Analysis Indicators
Immuneering Corp stock analysis indicators help investors evaluate how Immuneering Corp stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Immuneering Corp shares will generate the highest return on investment. By understating and applying Immuneering Corp stock analysis, traders can identify Immuneering Corp position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 59.4 M | |
| Common Stock Shares Outstanding | 31.1 M | |
| Total Stockholder Equity | 41.4 M | |
| Property Plant And Equipment Net | 4.8 M | |
| Cash | 36.1 M | |
| Accounts Payable | 2 M | |
| 50 Day M A | 1.7962 | |
| Total Current Liabilities | 7.5 M | |
| Non Current Assets Total | 13.1 M | |
| Non Currrent Assets Other | 1.3 M | |
| Stock Based Compensation | 6.5 M |
Additional Tools for Immuneering Stock Analysis
When running Immuneering Corp's price analysis, check to measure Immuneering Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immuneering Corp is operating at the current time. Most of Immuneering Corp's value examination focuses on studying past and present price action to predict the probability of Immuneering Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immuneering Corp's price. Additionally, you may evaluate how the addition of Immuneering Corp to your portfolios can decrease your overall portfolio volatility.